Literature DB >> 12544509

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

Charis P Zamber1, Jatinder K Lamba, Kazuto Yasuda, Jennifer Farnum, Kenneth Thummel, John D Schuetz, Erin G Schuetz.   

Abstract

The aim of this study was to identify the extent of genetic variability in breast cancer resistance protein (BCRP) in humans. We first analysed the sequence of BCRP cDNA from human livers and from human intestines phenotyped for expression of intestinal BCRP. We then determined the frequency of all known coding single nucleotide polymorphisms (cSNPs) using DNA from individuals representing 11 different ethnic populations. Nine SNPs including four non-synonymous and three synonymous cSNPs and two intronic SNPs were identified. Of the missense mutations, exon 2 SNP (G34A) resulted in a V12M change; exon 5 SNP (C421A) resulted in a Q141K substitution; exon 6 SNP (A616C) resulted in an I206L amino acid substitution; and exon 15 SNP (A1768T) resulted in a N590Y change in the BCRP protein. The two most frequent polymorphisms identified in the human population studied were the G34A and C421A transitions. There was marked variation in BCRP genotypes and allele frequencies in the different populations. BCRP mRNA was phenotyped in human small bowel intestinal samples by real-time polymerase chain reaction and BCRP protein was analysed on immunoblots of tissue from the same individuals. There was a 78-fold variation in expression of BCRP mRNA and significant variation in BCRP protein expression in human intestine. Expression of intestinal BCRP mRNA and protein was not different between persons expressing the common Gln141 allele compared to the Lys141 allele. Thus, common natural allelic variants of BCRP have been identified, and did not influence interindividual variation in expression of BCRP mRNA in human intestine, but remain to be tested for their effect on BCRP function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544509     DOI: 10.1097/00008571-200301000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  67 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 2.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

Review 3.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

Authors:  Toshihisa Ishikawa; Ai Tamura; Hikaru Saito; Kanako Wakabayashi; Hiroshi Nakagawa
Journal:  Naturwissenschaften       Date:  2005-10

Review 4.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

5.  Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2010-10-23       Impact factor: 2.953

6.  Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.

Authors:  Xue Bai; Bin Zhang; Ping Wang; Guan-Lei Wang; Jia-Li Li; Ding-Sheng Wen; Xing-Zhen Long; Hong-Shuo Sun; Yi-Bin Liu; Min Huang; Shi-Long Zhong
Journal:  Acta Pharmacol Sin       Date:  2018-06-27       Impact factor: 6.150

7.  Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

Authors:  John F Deeken; Robert W Robey; Suneet Shukla; Kenneth Steadman; Arup R Chakraborty; Balasubramanian Poonkuzhali; Erin G Schuetz; Susan Holbeck; Suresh V Ambudkar; Susan E Bates
Journal:  Mol Pharmacol       Date:  2009-07-24       Impact factor: 4.436

Review 8.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.

Authors:  Tomoka Furukawa; Kanako Wakabayashi; Ai Tamura; Hiroshi Nakagawa; Yoshihiro Morishima; Yoichi Osawa; Toshihisa Ishikawa
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

Review 10.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.